Assessment of phosphorus bioavailability from animal manures applied to portuguese soils and site vulnerability to phosphorus losses

Research project PTDCAGR-PRO/112127/2009To assess phosphorus (P) dynamics and provide scientific knowledge to create an evaluation tool to identify the risk of P loss to surface water bodies in soil amended with animal manures

Ciclo do fósforo em agroecossistemas: Efeito da fertilização fosfatada com adubos minerais ou com resíduos orgânicos de pecuária

Comunicação oral da qual só está disponível o resumo.Ciclo do fósforo em agroecossistemas: Efeito da fertilização fosfatada com adubos minerais ou com resíduos orgânicos de pecuária.Trabalho financiado pelo projeto FCT PTDC/AGRPRO/ 112127/2009, “Assessment of phosphorus bioavailability from animal manures applied to Portuguese soils and site vulnerability to phosphorus losses”, 2011-2013

Fertilizantes orgânicos : efeito na fertilidade do solo e na produção de azevém

Fertilizantes orgânicos : efeito na fertilidade do solo e na produção de azevém

Animal manures applied to soil: phosphorus bioavailability, losses to water and erosion

Comunicação oral da qual só está disponível o resumo.Phosphorus (P) is a non renewable resource which highlights the significance of developing and using alternative sources of P for a sustainable agriculture. Animal manure is an option but its application to soils to meet crop nitrogen needs requires careful management practices to minimize freshwater eutrophication. The aim of this work was to evaluate the partitioning of applied P between plant uptake, losses to water, and erosion losses when using different animal manures and a mineral P fertilizer. A field trial was conducted at an erosion experimental station. The treatments were: Control (0 kg P/ha); cattle manure; solid fraction of pig and duck slurry and superphosphate, each applied at a rate of 50 kg P/ha after Lolium sp was sown. Soil samples from each trial were collected over the 9-month study and the water extractable soil P determined. It was found that desorption of P from all additions rapidly increased soon after P application (2 weeks). After that water extractable soil P remained fairly constant. While duck slurry desorbed the largest concentration of P, all sources have the potential to desorb P that could accelerate eutrophication. Plant uptake of P was greater with cattle manure added and released the least amount of P to water compared with the other sources of P. The partitioning of applied P between plant uptake and losses to runoff and sediments ranged between 5-12 % with the higher values in Duck treatment. Animal manures significantly increased soil Olsen-P, plant production and P uptake relative to mineral fertilizer. Animal manures can be considered as a source of available P nevertheless to avoid eutrophication risks increase plant P use efficiency is also important

Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients

Background Cysteinyl leukotrienes (CysLT) are potent inflammation-promoting mediators, but remain scarcely explored in COVID-19. We evaluated urinary CysLT (U-CysLT) relationship with disease severity and their usefulness for prognostication in hospitalized COVID-19 patients. The impact on U-CysLT of veno-venous extracorporeal membrane oxygenation (VV-ECMO) and of comorbidities such as hypertension and obesity was also assessed. Methods Blood and spot urine were collected in severe (n = 26), critically ill (n = 17) and critically ill on VV-ECMO (n = 17) patients with COVID-19 at days 1-2 (admission), 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point. U-CysLT were measured by ELISA. Routine markers, prognostic scores and outcomes were also evaluated. Results U-CysLT did not differ between groups at admission, but significantly increased along hospitalization only in critical groups, being markedly higher in VV-ECMO patients, especially in hypertensives. U-CysLT values during the first week were positively associated with ICU and total hospital length of stay in critical groups and showed acceptable area under curve (AUC) for prediction of 30-day mortality (AUC: 0.734, p = 0.001) among all patients. Conclusions U-CysLT increase during hospitalization in critical COVID-19 patients, especially in hypertensives on VV-ECMO. U-CysLT association with severe outcomes suggests their usefulness for prognostication and as therapeutic targets.This work was supported by a RESEARCH 4 COVID-19 grant (project 519, reference number: 613690173) from FCT-Fundacao para a Ciencia e a Tecnologia (special support for rapid implementation projects for innovative response solutions to COVID-9 pandemic). CS-P is a recipient of a Ph.D. fellowship from FCT and MedInUP (UI/BD/150816/2020). P-PT was supported by a research contract within the scope of the RIFF-HEART project funded by FEDER via COMPETE, Portugal 2020-Operational Programme for Competitiveness and Internationalization (POCI) (POCI-01-0145-FEDER-032188) and by FCT (PTDC/MEC-CAR/32188/2017). Open access funding provided by FCT|FCCN (b-on)

Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure

OBJECTIVE: Only a limited proportion of patients needing pharmacological control of portal hypertension are hemodynamic responders to propranolol. Here we analyzed the effects of zolmitriptan on portal pressure and its potential interaction with propranolol. METHODS: ZOLMITRIPTAN, PROPRANOLOL OR BOTH WERE TESTED IN TWO RAT MODELS OF PORTAL HYPERTENSION: common bile duct ligation (CBDL) and CCl4-induced cirrhosis. In these animals we measured different hemodynamic parameters including portal venous pressure, arterial renal flow, portal blood flow and cardiac output. We also studied the changes in superior mesenteric artery perfusion pressure and in arterial wall cAMP levels induced by zolmitriptan, propranolol or both. Moreover, we determined the effect of splanchnic sympathectomy on the response of PVP to zolmitriptan. RESULTS: In both models of portal hypertension zolmitriptan induced a dose-dependent transient descent of portal pressure accompanied by reduction of portal flow with only slight decrease in renal flow. In cirrhotic rats, splanchnic sympathectomy intensified and prolonged zolmitriptan-induced portal pressure descent. Also, propranolol caused more intense and durable portal pressure fall when combined with zolmitriptan. Mesenteric artery perfusion pressure peaked for about 1 min upon zolmitriptan administration but showed no change with propranolol. However propranolol enhanced and prolonged the elevation in mesenteric artery perfusion pressure induced by zolmitriptan. In vitro studies showed that propranolol prevented the inhibitory effects of β2-agonists on zolmitriptan-induced vasoconstriction and the combination of propranolol and zolmitriptan significantly reduced the elevation of cAMP caused by β2-agonists. CONCLUSION: Zolmitriptan reduces portal hypertension and non-selective beta-blockers can improve this effect. Combination therapy deserves consideration for patients with portal hypertension failing to respond to non-selective beta-blockers